Keeler Thomas Management LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 1,771 shares of the company's stock, valued at approximately $925,000.
A number of other large investors also recently made changes to their positions in the stock. Aurora Investment Managers LLC. bought a new stake in IDEXX Laboratories in the second quarter valued at about $2,442,000. National Pension Service lifted its stake in IDEXX Laboratories by 5.6% in the second quarter. National Pension Service now owns 129,305 shares of the company's stock valued at $68,071,000 after buying an additional 6,885 shares during the period. NewEdge Advisors LLC boosted its holdings in IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company's stock worth $8,552,000 after buying an additional 5,761 shares during the last quarter. Arizona State Retirement System boosted its holdings in IDEXX Laboratories by 4.9% during the second quarter. Arizona State Retirement System now owns 22,772 shares of the company's stock worth $11,988,000 after buying an additional 1,074 shares during the last quarter. Finally, Howard Capital Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $1,249,000. Institutional investors and hedge funds own 87.84% of the company's stock.
Key IDEXX Laboratories News
Here are the key news stories impacting IDEXX Laboratories this week:
- Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported adjusted earnings of approximately $3.96–$3.98 per share versus the $3.71 consensus estimate. Revenue rose about 10% year over year to $1.21 billion, exceeding expectations of roughly $1.19 billion. IDEXX Laboratories Q3 earnings report
- Positive Sentiment: Recurring diagnostics remained the key growth engine. Recurring diagnostic revenue to veterinarians increased about 11%, demonstrating continued demand for IDEXX’s testing platforms and supporting the company’s earnings growth despite softer veterinary visit trends. IDEXX raises forecast
- Positive Sentiment: Management raised its full-year 2026 earnings and revenue guidance. The revised outlook suggests that IDEXX expects diagnostics growth, operating performance and customer adoption of its offerings to offset weakness in veterinary visit volumes. The guidance increase was the primary catalyst behind the strong stock reaction. IDEXX revises 2026 earnings guidance
- Neutral Sentiment: The earnings call reinforced a favorable long-term growth narrative. Management highlighted continued expansion in diagnostics, recurring revenue and productivity initiatives, which may support durable growth but also leaves the stock reliant on sustained premium valuation expectations. IDEXX Laboratories earnings call highlights
- Negative Sentiment: Margin trends and veterinary demand remain risks. Some reports noted that the higher profit forecast was not driven by stronger testing demand, while the margin outlook softened. Weak veterinary visits could pressure near-term volume growth if diagnostics expansion does not continue. IDEXX sales and margin outlook
Insider Activity
In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.79% of the stock is owned by company insiders.
IDEXX Laboratories Price Performance
IDXX opened at $671.64 on Tuesday. The stock has a market cap of $52.91 billion, a P/E ratio of 47.23 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The company has a fifty day simple moving average of $536.56 and a 200 day simple moving average of $573.88.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company's revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the company posted $3.22 earnings per share. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have recently commented on IDXX shares. JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating for the company in a research note on Friday, October 16th. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. KeyCorp began coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They set a "sector weight" rating on the stock. Finally, UBS Group decreased their price objective on shares of IDEXX Laboratories from $670.00 to $627.00 and set a "neutral" rating for the company in a report on Tuesday, October 27th. Eight analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $721.67.
Read Our Latest Analysis on IDXX
IDEXX Laboratories Company Profile
(
Free Report)
IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.
IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.
Read More
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.